Scedosporium apiospermum (Pseudoallescheria boydii) Infection in Lung Transplant Recipients

Journal of Heart and Lung Transplantation

Volumn 26, Issue 4, 2007, Pages 350-356

  Sahi, Hina ^a   Avery, Robin K ^b   Minai, Omar A ^a   Hall, Geraldine ^b   Mehta, Atul C ^a   Raina, Paola ^c   Budev, Marie ^a  

^a Allergy   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; AZATHIOPRINE; CASPOFUNGIN; COTRIMOXAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIPENEM; ITRACONAZOLE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; POSACONAZOLE; PREDNISONE; STEROID; TACROLIMUS; TERBINAFINE; TRIAZOLE DERIVATIVE; VALGANCICLOVIR; VANCOMYCIN; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLUS; CASE REPORT; CONVALESCENCE; DEBRIDEMENT; DEMOGRAPHY; DRUG EFFICACY; DRUG SUBSTITUTION; EARLY DIAGNOSIS; FEMALE; FUNGUS CULTURE; FUNGUS ISOLATION; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LUNG TRANSPLANTATION; MALE; MYCOSIS; MYOPATHY; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATIENT MONITORING; PETRIELLIDIUM BOYDII; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT; RETROSPECTIVE STUDY; SCEDOSPORIUM APIOSPERMUM; TREATMENT OUTCOME;

ADULT; ANTIFUNGAL AGENTS; BREAST IMPLANTS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; DATABASES, FACTUAL; FATAL OUTCOME; FEMALE; HUMANS; LUNG TRANSPLANTATION; MADUROMYCOSIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RESPIRATORY SYSTEM; RETROSPECTIVE STUDIES; SCEDOSPORIUM;

EID: 33947703192     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.01.011     Document Type: Article

References (34)

1. Husain S., Alexander B.D., Munoz P., et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 37 (2003) 221-229
2. Husain S., Munoz P., Forrest G., et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 40 (2005) 89-99
3. Raj R., and Frost A.E. Scedosporium apiospermum fungemia in a lung transplant recipient. Chest 121 (2002) 1714-1716
4. Tamm M., Malouf M., and Glanville A. Pulmonary Scedosporium infection following lung transplantation. Transpl Infect Dis 3 (2001) 189-194
5. Gil-Lamaignere C., Winn R.M., Simitsopoulou M., Maloukou A., Walsh T.J., and Roilides E. Interferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. Med Mycol 43 (2005) 253-260
6. Shah S.S., Karnak D., Budev M., Avery R.K., and Mehta A.C. Endobronchial Pseudoallescheria boydii in lung transplant patient with cystic fibrosis. J Bronchol 14 (2007) 48-50
7. Afeltra J., Dannaoui E., Meis J.F., Rodriguez-Tudela J.L., and Verweij P.E. In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. Antimicrob Agents Chemother 46 (2002) 3323-3326
8. Cimon B., Carrere J., Vinatier J.F., Chazalette J.P., Chabasse D., and Bouchara J.P. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 19 (2000) 53-56
9. Castiglioni B., Sutton D.A., Rinaldi M.G., Fung J., and Kusne S. Pseudallescheria boydii (anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) 81 (2002) 333-338
10. Musk M., Chambers D., Chin W., Murray R., and Gabbay E. Successful treatment of disseminated Scedosporium infection in 2 lung transplant recipients: review of the literature and recommendations for management. J Heart Lung Transplant 25 (2006) 1268-1272
11. Panackal A.A., and Marr K.A. Scedosporium/Pseudallescheria infections. Semin Respir Crit Care Med 25 (2004) 171-181
12. Sandhu G.S., Kline B.C., Stockman L., and Roberts G.D. Molecular probes for diagnosis of fungal infections. J Clin Microbiol 33 (1995) 2913-2919
13. Radford S.A., Johnson E.M., and Warnock D.W. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 41 (1997) 841-843
14. Sabatelli F., Patel R., Mann P.A., et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 50 (2006) 2009-2015
15. Minassian B., Huczko E., Washo T., Bonner D., and Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin Microbiol Infect 9 (2003) 1250-1252
16. Torre-Cisneros J., Gonzales-Ruiz A., Hodges M.R., et al. Voriconazole for the treatment of S. apiospermum and S. prolificans infection (2000) (Abstract 305) In: 38th Infectious Disease Society of America Meeting, New Orleans, LA.
17. Perfect J.R., Marr K.A., Walsh T.J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36 (2003) 1122-1131
18. Gonzalez G.M., Tijerina R., Najvar L.K., et al. Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob Agents Chemother 47 (2003) 1436-1438
19. Howden B.P., Slavin M.A., Schwarer A.P., and Mijch A.M. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 22 (2003) 111-113
20. Meletiadis J., Mouton J.W., Meis J.F., and Verweij P.E. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 47 (2003) 106-117
21. Verweij P.E., Cox N.J., and Meis J.F. Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy. Eur J Clin Microbiol Infect Dis 16 (1997) 26-28
22. Graybill J.R., Bocanegra R., Gonzalez G.M., and Najvar L.K. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 52 (2003) 656-662
23. Heyn K., Tredup A., Salvenmoser S., and Muller F.M. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 49 (2005) 5157-5159
24. Yustes C., and Guarro J. In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp. Antimicrob Agents Chemother 49 (2005) 3498-3500
25. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 20 (2003) 121-136
26. Idigoras P., Perez-Trallero E., Pineiro L., et al. Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999. Clin Infect Dis 32 (2001) E158-E165
27. Gil-Lamaignere C., Maloukou A., Rodriguez-Tudela J.L., and Roilides E. Human phagocytic cell responses to Scedosporium prolificans. Med Mycol 39 (2001) 169-175
28. Gil-Lamaignere C., Roilides E., Maloukou A., Georgopoulou I., Petrikkos G., and Walsh T.J. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 50 (2002) 1027-1030
29. Gil-Lamaignere C., Roilides E., Mosquera J., Maloukou A., and Walsh T.J. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 46 (2002) 2234-2237
30. Bouza E., Munoz P., Vega L., Rodriguez-Creixems M., Berenguer J., and Escudero A. Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor. Clin Infect Dis 23 (1996) 192-193
31. Abzug M.J., and Walsh T.J. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 23 (2004) 769-773
32. Munoz P., Marin M., Tornero P., Martin Rabadan P., Rodriguez-Creixems M., and Bouza E. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 31 (2000) 1499-1501
33. Symoens F., Knoop C., Schrooyen M., et al. Disseminated Scedosporium apiospermum infection in a cystic fibrosis patient after double-lung transplantation. J Heart Lung Transplant 25 (2006) 603-607
34. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole (POS) vs fluconazole (FLU) for prophylaxis of invasive fungal infections (IFIs) in allogeneic hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD): results of a multicenter trial (2005) Abstract M-716. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC